Gene therapy successes Flashcards

1
Q

What is duchenne muscular dystrophy?

A

X-linked recessive disorder.

Degeneration and regeneration of skeletal
and cardiac muscles.

Associated with severe progressive muscle
weakness.

Affected boys cannot walk by 10 years of
age.

Life expectancy is around 20 to 35 years,
death due to heart or respiratory failures.

Due to mutations in dystrophin gene.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the dystrophin gene?

A

The dystrophin gene is one of the longest human genes identified.

Codes for linear cytoplasmic protein that supports muscle fibres.

Major protein in the dystrophin-associated protein complex (DAPC).

The DAPC connects cytoskeleton of muscle fibres to extracellular matrix through the cell membrane.

Important for muscle fibre strength and flexibility.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What types of mutations lead to duchenne muscular dystrophy?

A

Deletion hotspots around exons 45-53 (cluster I) or exons 2-20 (cluster II).

Missense mutations distributed throughout, introducing premature stop codons.

Duplications.

Out-of-frame mutations or premature stop codons lead to no functional protein.

Becker’s muscular dystrophy:
Protein-binding N and C-terminal domains still present as no change in reading frame. The shorter protein has some functionality.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Why is duchenne muscular dystrophy suitable for gene therapy?

A

It is a monogenic recessive disorder.

Mapped to mutations in a single gene.

Currently no cure for DMD.

Physiotherapy, corticosteroids, creatine medication to improve muscle strength and slow progress of muscle weakening.

Translarna (Ataluren) available to some patients with nonsense mutation – allows ribosome to read-through premature stop codon in mRNA.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is the process of exon skipping?

A

Exon skipping occasionally occurs during splicing of primary transcript, observed in revertant
fibres in DMD.

Can be induced with antisense oligonucleotides that mask splice sites.

Protein with partial deletions can still have functional benefits.

ON1 binding to exon 44 improved phenotype in mouse model.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the obstacles with oligonucleotide drugs?

A

Method of administration:

Lack of effective distribution away from the injection site.

> 300 muscles make up the total musculature in the human body.

Systemic delivery system required.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are the obstacles with AAV vectors?

A

Potential problems:

High dose of virus needed to express required amounts of protein.
Immune responses against AAV may limit effectiveness of subsequent deliveries.

How can this be overcome?

Transient immunosuppression.
Recombinant AAV that are less immunogenic.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Why is cystic fibrosis suitable for gene therapy?

A

CF is a monogenic disorder.

Mapped to mutations in a single gene.

CFTR modulators target the underlying cause of the disease but only work on some mutations.

Gene replacement therapies are most promising hope for a cure.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How are adenoviral vectors used to deliver CFTR genes?

A

Ex vivo transfer of CFTR gene using adenovirus and retrovirus vectors caused cells to produce the CFTR protein.

Adenoviruses cause common colds.

Genetically engineered to non-harmful versions that carried the target gene.

Sequence does not integrate into host genome.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the disadvantages of adenovirus vectors?

A

No dramatic changes in the long-term.

Sequence does not integrate, and so treatment must be repeated.

Host immune system was producing a response against the adenovirus and destroying the vector.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How can delivery be improved?

A

Next-generation AAV vectors that have increased infectivity to reach more cells in the lung.

Shorter CFTR gene to allow additional stronger promoter sequences in the vector.

Lentiviruses that integrate the target gene into host genome.

Lipid nanoparticles instead of viral vectors.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the process of CRISPR/Cas 9 gene editing?

A

Patient’s CFTR gene can be edited to correct the
mutations.

Organoids taken from CF patients with no expression
of CFTR protein.

CRISPR/Cas9 gene editing of the CFTR gene.

Function of CFTR protein restored in the organoids.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are the different parts of the HIV genome?

A

gag: viral capsid.
pol: reverse transcriptase.
vpr: accessory protein involved in immune evasion.

tat: transactivator essential for gene expression, binds
TAR sequence.

rev: essential for export of unspliced mRNA into the cytoplasm.
env: binds CD4 and CCR5 or CXCR4 for entry.
nef: accessory protein downregulates CD4 and MHC1 expression.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the obstacles with current therapies?

A

Requires adherence.

Development of resistance.

Viral genome is integrated into host genome and therefore current therapies are not a cure.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

How can HIV be treated with gene/cell therapy strategies?

A

Targeting the virus.

Targeting host proteins.

Activating host immunity.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

How do ribozymes target HIV tat/vpr?

A

Ribozyme targeting HIV-1 tat/vpr genes - OZ1.

OZ1 delivered by MMLV retroviral vector to autologous CD34+ cells.

17
Q

What are the advantages of ribozymes targeting HIV tat/vpr?

A

Ex vivo strategy reduceslikelihood of insertional
mutagenesis.

Stem cells may provide solution for long-term.

Specificity in ribozyme action.

18
Q

What are the issues with targeting viruses?

A

HIV reverse transcriptase is error prone.

Allows virus to mutate fast and escape the treatment

How can this be overcome?

Target host genes essential for HIV replication e.g. CCR5 and CXCR4 are cell surface receptors essential for viral entry.

Can target host genes in combination with viral genes to minimise escape.

19
Q

Why is CCR5 a good target?

A

CCR5 is a co-receptor required for entry of macrophage-tropic strains of HIV, usually responsible for transmission.

Up to 16% of Europeans have CCR5Δ32 mutation that introduces a premature stop codon and no expression on the cell surface.

Individuals with homozygous Δ32 mutations show resistance to M-tropic strains of HIV, and heterozygotes show delayed progression to AIDS.